Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cancer Precision Medicine Inc. currently faces 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being reviewed by 1 distinct examiner, indicating a very focused scope of current prosecution activity. The presence of 1 pending action suggests that the company is not currently managing a large volume of active patent applications. This limited activity level allows the applicant to dedicate significant resources to a single ongoing dialogue with the patent office.
The prosecution is localized within 1 distinct art unit, which centralizes the technical evaluation of the company's filing. KINSEY WHITE, NICOLE ERIN is the busiest examiner for the portfolio, with 1 pending office action currently assigned. Because this examiner handles the active matter, they are responsible for the entirety of the company's workload at the patent office. This arrangement means the current legal strategy is entirely dependent on the specific feedback and prior art analysis provided by this single examiner, requiring a focused effort to overcome any cited rejections.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270590 | SARS-COV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | KINSEY WHITE, NICOLE ERIN | 61d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270590 | SARS-COV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | KINSEY WHITE, NICOLE ERIN | 61d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270590 | SARS-COV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME | KINSEY WHITE, NICOLE ERIN | 1672 | §102§103 | Final Rejection | 61d | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial